Clinical Trial

Luspatercept for CIA in AML

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.
Trial Details
NCT Number NCT07663864
Lead Sponsor Guangdong Second Provincial General Hospital
Collaborators: Nanfang Hospital, Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, Guangzhou First People's Hospital, Affiliated Hospital of Guangdong Medical University, Guangzhou 8th People's Hospital
Conditions Chemotherapy-inducing Anemia
Enrollment 40 participants
Start Date 2026-06-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23